is suggested, and transplantation should be taken into Primary sclerosing cholangitis (PSC) is a chronic inconsideration at scores above 4. (HEPATOLOGY 1996; flammatory disease associated in 10% to 36% of those 23:1105-1111.) with hepatobiliary malignancies, which are, in the majority of cases, not
Recurrence of primary sclerosing cholangitis following liver transplantation
β Scribed by Ivo W. Graziadei; Russell H. Wiesner; Kenneth P. Batts; Paul J. Marotta; Nicholas F. LaRusso; Michael K. Porayko; J. Eileen Hay; Gregory J. Gores; Michael R. Charlton; Jurgen Ludwig; John J. Poterucha; Jeffery L. Steers; Ruud A. Krom
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 311 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Recurrence of primary sclerosing cholangitis (PSC) following liver transplantation has been suggested; however, it has not been fully defined because of numerous complicating factors and the lack of diagnostic criteria. In the present study, we investigated the recurrence of PSC by developing strict criteria and applying them to a large cohort of PSC patients who underwent liver transplantation. Between March 1985 and June 1996, 150 PSC patients underwent liver transplantation at the Mayo Clinic; mean follow up was 55 months. The incidence of nonanastomotic biliary strictures and hepatic histologic findings suggestive of PSC were compared between patients transplanted for PSC and a non-PSC transplant control group. Our definition of recurrent PSC was based on characteristic cholangiographic and histologic findings that occur in nontransplant PSC patients. By using strict criteria, 30 patients with other known causes of posttransplant nonanastomotic biliary strictures were excluded leaving 120 patients for analysis of recurrence of PSC. We found evidence of PSC recurrence after liver transplantation in 24 patients (20%). Of these, 22 out of 24 patients showed characteristic features of PSC on cholangiography and 11 out of 24 had compatible hepatic histologic abnormalities with a mean time to diagnosis of 360 and 1,350 days, respectively. Both cholangiographic and hepatic histologic findings suggestive of PSC recurrence were seen in nine patients. The higher incidence and later onset of nonanastomotic biliary strictures in patients with PSC compared with a non-PSC control group is supportive of the fact that PSC does recur following liver transplantation. We were unable to identify specific clinical risk factors for recurrent PSC, and the overall patient and graft survival in patients with recurrent PSC was similar to those without evidence of recurrence. Our observations provide convincing evidence that PSC frequently recurs in the hepatic allograft using strict inclusion and exclusion criteria. (HEPATOLOGY 1999;29:1050-1056.)
PSC is a chronic cholestatic liver disease characterized by diffuse fibrosing inflammation usually involving both the Abbreviation: PSC, primary sclerosing cholangitis. From the Liver Transplant Center, Mayo Clinic,
π SIMILAR VOLUMES
Liver transplantation is the only effective therapeutic option for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC). In this study, we analyzed a single center's experience with 150 consecutive PSC patients who received 174 liver allografts. Mean follow-up was 55 mon
Between February 26, 1981, and July 30, 1987, 36 patients underwent orthotopic liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Three of the 36 recipients died within 3 mo because of graft nonfunction or surgical complications. The other 33 (92%) lived for